Thursday, 16 August 2018
Latest news
Main » More Breast Cancer Patients Can Skip Chemo - Gene Test

More Breast Cancer Patients Can Skip Chemo - Gene Test

07 June 2018

According to various sites, a woman suffering from an advanced stage of breast cancer that had spread throughout her body was completely cleared off the disease.

A leading oncologist said the findings will lead to a "fundamental change" in how the disease is treated.

As of January 2018, there are more than 3.1 million women with a history of breast cancer in the U.S. This includes women now being treated and women who have finished treatment.

Sunday's results came from a federally sponsored trial called TailorX, which was created to help doctors more precisely tailor treatments for early-stage breast cancer.

"I think it's very exciting news the breast cancer community has been waiting for the information confirming to us we do not need to be overtreating patients anymore", said Dr. Nicole Figueredo, breast surgeon at Florida Hospital.

The study was funded by the National Cancer Institute. By continuing the personalized assessment of an individual's cancer recurrence risk, oncologists can more effectively determine specifically-tailored treatments based on that patient's genomic results.

More news: How to watch French Open 2018 clash online

Very high scores are at increased risk of the cancer spreading, and those patients have benefited a lot by chemotherapy.

Thousands of breast cancer patients may be safely spared gruelling chemotherapy following a landmark study. "We're saving people these side effects". The study also has the potential to improve access to health care by keeping costs down for women who do not need chemotherapy, Olopade said.

The results show that all women over 50 with a recurrence score of 0 to 25 can be spared chemotherapy and its toxic side effects.

The confusion comes from a genetic test called Oncotype DX that rates the likelihood of breast cancer recurrence on a 100-point scale. "Therefore they should get the chemotherapy along with hormonal treatment".

The study reportedly found that gene tests on the tumor samples could identify the women who are eligible to skip chemotherapy.

"This is another significant step towards personalised breast cancer treatment and we hope these practice-changing findings will now help refine our use of chemotherapy on the NHS", she said. Breast cancer remains the second most common cause of death from cancer among females in Australia. She hadn't felt any lumps or symptoms and had no family history of breast cancer before the diagnosis, she said. Longer-term effects of chemotherapy include infertility and heart failure.

More news: Mexico aims tariffs at Trump country, sees NAFTA complications

The overall survival rate was similar: 93.9% for those who received hormone therapy alone and 93.8% for those who received both therapies.

The result: After an average follow-up of 7.5 years, the researchers saw no added benefit in this group to adding chemotherapy to the treatment mix.

But, researchers say some women 50 and younger in high-risk groups might still need chemo.

The findings will lead to a "fundamental change" in the way the disease is treated, a leading oncologist said, with an estimated 3,000 to 5,000 United Kingdom women likely to avoid chemotherapy every year as a result.

"Oncologists have been getting much smarter about dialing back treatment so that it doesn't do more harm than good", Steven Katz, a University of MI researcher who examines medical decision-making, told the Washington Post.

More news: SpaceX delays plans to send tourists around Moon, says report

More Breast Cancer Patients Can Skip Chemo - Gene Test